Mucosal vaccine adjuvants containing bacterial flagellins as...

Details Mucosal vaccine adjuvants containing bacterial flagellins as... Mucosal vaccine adjuvants containing bacterial flagellins as...

2011-03-29

2011-03-29

Zeman, Robert A. (Department: 1645)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

Bacterium or component thereof or substance produced by said...

C424S190100, C530S350000

Reexamination Certificate

active

07914802

ABSTRACT:
The present invention relates to mucosal vaccine adjuvants containing flagellins, the structural component of flagella, originated fromVibrio vulnificus, Salmonella typhimurium, andListeria monocytogenesas an active component.

REFERENCES:
patent: 02085933 (2002-10-01), None
patent: WO02085933 (2002-10-01), None
patent: 2004022092 (2004-03-01), None
McSorley et al. 2002 Journal of Immunology vol. 169 pp. 3914-3919.
Wu et al 1989 Proc. Natl Acad Science USA vol. 86 pp. 4726-4730.
Kim et al Biochemical and Biophysical Research Communications 304 (2003) pp. 405-410.
Amaro et al Current Microbiology vol. 25 (1992) pp. 99-104.
Cuadros C. et al, “Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.”In Infect. Iuumn., vol. 27, No. 5, May 2004, pp. 2810-2816.
Sbrogio-Almeida M.E., et al., “Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuatedSalmonellavaccine strains,”In Infect. Immun., vol. 72, No. 5, May 2004, pp. 2546-2555.
Kodama C., et al., “Salmonellaflagellin is not a dominant protective antigen in oral immunization with attenuated live vaccine strains,”In Infect. Immun., vol. 72, No. 4, Apr. 2004, pp. 2449-2451.
Jiang, Zi-Hua, et al., “Synthetic Vaccines: The Role of Adjuvants in Immune Targeting,” Current Medicinal Chemistry, 2003, 10, 1423-1439.
McSorley, S.J., et al., “Bacterial Flagellin Is An Effective Adjuvant for CD4+ T Cells in Vivo,” J. of Immunology, 169: 3914-3919 (2002).
Smith K D et al: “Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility” Nature Immunology, Nature Publishing Group, GB, vol. 4, No. 12, Dec. 1, 2003, pp. 1247-1253, XP002999619, ISSN: 1529-2908 *p. 1248*.
Database UniProt [Online] Mar. 1, 2003, “SubName: Full=Flagellin FlaE;” XP002526974 retrieved from EBI accession No. UNIPROT.
Supplementary European Search Report dated Jul. 7, 2009.
European Patent Office, Office Action issued in application 05 721 779.6, dated Nov. 5, 2009.
Gov't of India Patent Office, First Examination Report issued in application No. 806/MUMNP/2006 dated Dec. 31, 2009.
Wu, Jane Y. et al., “Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain ofSalmonella,” Proc. Natl. Acad. Science, USA, vol. 86, pp. 4726-4730, Jun. 1989.
Chinese Office Action issued in application No. 200580002321.4 on Mar. 11, 2010 with English translation.
Indian Patent Office Examination Report issued in counterpart Indian Application No. 806/MUMNP/2006 dated Jul. 8, 2010.

Affiliated with

Also associated with

Rating

Mucosal vaccine adjuvants containing bacterial flagellins as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mucosal vaccine adjuvants containing bacterial flagellins as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mucosal vaccine adjuvants containing bacterial flagellins as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2754526